Q3 results highlighted continued growth in Vyvgart sales, while its acquisition of Forte Biosciences broadened the company's late-stage pipeline ahead of a potentially important phase 3 readout for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results